ImageSource Recognized as an Aspirant in Everest Group's 2025 Intelligent Document Processing (IDP) PEAK Matrix® Assessment
OLYMPIA, Wash.--(BUSINESS WIRE)--ImageSource, Inc., the enterprise automation company behind the ILINX® platform, announced today its recognition as an Aspirant in the 2025 Everest Group Intelligent Document Processing (IDP) PEAK Matrix® Assessment. This inaugural appearance underscores ImageSource's growing momentum in delivering intelligent content automation, particularly in high-compliance business processes and industries such as government and financial services.
"Being named an Aspirant on the Everest Group IDP PEAK Matrix® is an important milestone for our team,' said Terry Sutherland, CEO of ImageSource. 'This recognition validates our commitment to delivering trusted, results-driven automation to customers."
The annual PEAK Matrix® Assessment by Everest Group evaluates technology providers based on their market impact, vision, and capability to deliver intelligent document processing solutions. As an Aspirant, ImageSource has been recognized for its deep domain expertise, configurable workflows and customer-centric approach to transforming how organizations extract, classify and act on information across content types, systems and outcomes.
'Being named an Aspirant on the Everest Group IDP PEAK Matrix® is an important milestone for our team,' said Terry Sutherland, CEO of ImageSource. 'We've made strategic investments in AI innovation, expanding ILINX capabilities with retrieval-augmented generation (RAG), domain-specific language model (DSLM) and visual language model (VLM) creation, with no-code design tools and hybrid deployment models which make intelligent document processing faster, more accurate and secure. This recognition validates our commitment to delivering trusted, results-driven automation to our customers.'
ImageSource's ILINX platform leverages machine learning, natural language processing and intelligent data extraction to accelerate time to value across diverse use cases — ranging from claims and invoice processing to licensing, permitting and benefits eligibility. The company's unique end-to-end content pipeline, from acquisition to intelligent document processing to retention, make AI-powered processes a reality on data specific to an organization.
In addition to its technology strengths, ImageSource was recognized for its strong implementation track record and longstanding partnerships with public sector organizations and Fortune 500 enterprises. Customers cite ILINX's flexibility, low-code extensibility and built-in security as key differentiators in achieving digital transformation goals.
'This is just the beginning,' said Marni Carmichael, VP of marketing at ImageSource. 'Our roadmap is focused on accelerating intelligent automation across entire customer journeys. We're honored to be included in Everest Group's research and look forward to climbing the matrix in the years ahead.'
For more information about ImageSource and the ILINX intelligent document processing platform, visit www.imagesourceinc.com.
About ImageSource
ImageSource, Inc. makes process innovation easy with advanced solutions built on ILINX®, the world's most flexible process-improvement platform, delivered by a team of experts committed to customer-partner success. Leveraging proven technology and deep implementation expertise, ImageSource empowers leading enterprises and government organizations to reduce risk, modernize operations, unlock revenue and transform the customer experience. For more information, visit www.imagesourceinc.com, or call (360) 943-9273
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
32 minutes ago
- Business Wire
Deadline Approaching: Fortrea Holdings Inc. (FTRE) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 1, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Fortrea Holdings Inc. ('Fortrea' or the 'Company') (NASDAQ: FTRE) securities between , inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FORTREA HOLDINGS INC. (FTRE), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On September 25, 2024, the investment bank Jefferies downgraded Fortrea from buy to hold, citing perceived weaknesses in the Company's business model as a contract research organization ('CRO') amid pressure on biotechnology funding and that the cost savings Fortrea expects to achieve by existing transition services agreements ('TSAs') are 'not as material as one might think.' On this news, Fortrea's stock price fell $2.73, or 12.3%, to close at $19.48 per share on September 25, 2024, thereby injuring investors. Then, on December 6, 2024, Baird Equity Research stated that '[g]iven our ongoing concerns around the sector, [Fortrea's] choppy history post spin, and lack of clarity on the abrupt communications course change, we cannot recommend an actionable investment (buy or sell)[.]' On this news, Fortrea's stock price fell $1.90, or 8.1%, to close at $21.67 per share on December 6, 2024. Then, on March 3, 2025, before the market opened, Fortrea announced financial results for the fourth quarter and full year 2024, revealing the Company had missed its previously announced guidance for revenue and adjusted EBITDA for the full year 2024. The Company's financial results revealed full year adjusted EBITDA of $202.5 million, well below the Company's previously announced guidance of $220 million to $240 million. The Company also revealed full year revenue of $2.696 billion, which missed previously announced guidance of $2.7 billion to $2.725 billion. The Company further revealed financial guidance for the full year 2025, which projected declines in revenue and adjusted EBITDA, with revenues of $2.450 billion to $2.550 billion and adjusted EBITDA in the range of $170 million to $200 million. Thomas Pike ('Pike'), the Company's then-Chief Executive Officer ('CEO'), explained that 'full-service work for projects from the pre-spin period,' 'have less revenue and less profitability' and 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' Pike further revealed 'this older versus newer mix issue will continue to negatively impact our financial performance during 2025.' On this news, Fortrea shares fell $3.47, or 25.1%, to close at $10.38 per share on March 3, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (3) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Fortrea securities during the Class Period, you may move the Court no later than August 1, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
an hour ago
- Business Wire
Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. ('Organon' or the 'Company') (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR ORGANON INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company's dividend payout, from $0.28 to $0.02 and would 'redirect those funds to debt reduction.' On this news, Organon's stock price fell $3.48, or 26.9%, to close at $9.45 per share on May 1, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Organon's optimistic reports of the dividend payout as the Company's 'number one priority,' were offset by Organon's newly implemented debt reduction strategy, thus, leading to a drastic decrease – over 70% – of the quarterly dividend; (2) Organon planned to prioritize debt reduction following the Company's acquisition of Dermavant; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Organon securities during the Class Period, you may move the Court no later than July 22, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
an hour ago
- Yahoo
La Jolla Cosmetic Medical Spa Opens Third Location in Temecula on June 2nd
San Diego's Most Trusted Med Spa Expands to the Inland Empire with Award-Winning Aesthetic Services TEMECULA, Calif., June 5, 2025 /PRNewswire/ -- La Jolla Cosmetic Medical Spa (LJC), a leader in aesthetic care for over three decades, is proud to announce the opening of its third medical spa location in Temecula, California, which opened on Monday, June 2, 2025. This new location brings LJC's award-winning services to the heart of the Temecula Valley. Founded in 1988, the La Jolla Cosmetic brand has been a staple of San Diego's aesthetic community for 35+ years. With medical spa locations in La Jolla and Carlsbad, the practice has earned recognition as an 8-time winner of "Best of San Diego" and is currently named a Top 10 Allergan provider in the nation for injectables like BOTOX® and JUVÉDERM®. Now expanding into Riverside County, LJC continues its mission to make world-class aesthetic care more accessible across Southern California. "Opening in Temecula marks a major milestone in our mission to provide personalized, natural results and build long-term relationships with our patients across Southern California," said Lauren Amico Reed, PA-C, MMS, Co-founder of La Jolla Cosmetic Medical Spa. "We are thrilled to bring our team's expertise and renowned aesthetic care to this incredible community." The Temecula location will offer the full range of LJC's most popular non-surgical services, including: Injectables: BOTOX®, JUVÉDERM®, Sculptra®, and more Skin Rejuvenation: HALO® laser, BBL Hero®, threads, microneedling, and medical-grade facials Hair & Wellness Treatments: Regenerative treatments for hair thinning and sexual wellness injectables Patients can expect the same elevated experience that has made LJC a trusted name in aesthetics—from highly trained providers to personalized treatment plans, all in a welcoming, luxurious setting. With this new location, the brand strengthens its vision of blending clinical excellence with deep community connection. Appointments for the Temecula location can be booked at or by calling (858) 228-4542. To celebrate the launch, LJC is offering an exclusive pre-sale special: 40 units of BOTOX® for $299 for a limited time. Additionally, the official grand opening celebration will be held on Saturday, July 19, from 12 p.m. to 3 p.m. Guests can enjoy: Exciting giveaways Exclusive swag bags for the first arrivals Live treatment demos Light bites and refreshments Fun activities and a chance to tour the new space RSVP: La Jolla Cosmetic Medical Spa – Temecula Grand Opening Event! About La Jolla Cosmetic Medical SpaLa Jolla Cosmetic Medical Spa (LJC) has been helping patients look and feel their best since 2013. Known for delivering natural-looking results through expert providers, advanced technology, and personalized care, LJC sets the standard for aesthetic excellence. With medical spa locations in La Jolla, Carlsbad, and now Temecula, LJC continues to set the standard for aesthetic care in Southern California. View original content to download multimedia: SOURCE La Jolla Cosmetic Medical Spa Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
